Avizakimab, formerly known as BOS161721, represents a novel medicinal approach to treating immune-mediated disorders. This biological agent selectively targets IL18, a vital signaling molecule implicated in https://blanchedxcj797445.blog5.net/93129066/avizakimab-a-comprehensive-exploration-into-bos161721-s-promise